Market capitalization | $918.12m |
Enterprise Value | $770.00m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.10 |
P/S ratio (TTM) P/S ratio | 6.09 |
P/B ratio (TTM) P/B ratio | 10.52 |
Revenue growth (TTM) Revenue growth | 203.18% |
Revenue (TTM) Revenue | $150.86m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
5 Analysts have issued a Poseida Therapeutics Inc forecast:
5 Analysts have issued a Poseida Therapeutics Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | 151 151 |
203%
203%
|
|
Gross Profit | 145 145 |
229%
229%
|
|
EBITDA | -57 -57 |
57%
57%
|
EBIT (Operating Income) EBIT | -63 -63 |
54%
54%
|
Net Profit | -61 -61 |
54%
54%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. Its products pipeline include autologous and allogeneic chimeric antigen receptor T cell, or CAR-T. The company was founded by Eric M. Ostertag in 2014 and is headquartered in San Diego, CA.
Head office | United States |
CEO | Kristin Yarema |
Employees | 330 |
Founded | 2014 |
Website | www.poseida.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.